Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin + Gemcitabine in High-Risk NMIBC
NCT05943379Phase 2Recruiting
- Sponsor
- RemeGen
- Start
- Jun 2023
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin in non-muscle-invasive bladder cancer (NMIBC), sponsored by RemeGen. Started Jun 2023; status: recruiting.
02
Drugs
disitamab vedotin
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT05943379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05943379.